Javascript must be enabled to continue!
Severe Acute Respiratory Failure Associated with Viral Respiratory Infections: A Multidisciplinary Approach to Diagnosis, Pharmacotherapy, Respiratory Support, and Critical Care Management
View through CrossRef
Background: Severe acute respiratory failure caused by respiratory viruses is an important cause of intensive care unit admission and is associated with substantial morbidity and mortality. Advances in molecular diagnostics have increased the detection of respiratory viruses in lower respiratory tract infections, while also highlighting challenges in distinguishing true viral disease from asymptomatic carriage and bacterial-viral co-infection. Respiratory viruses can cause direct epithelial injury, dysregulated inflammation, alveolar damage, and systemic complications.
Aim: This narrative review aimed to summarize current evidence on the epidemiology, molecular diagnosis, pathophysiology, clinical consequences, outcomes, treatment, and prevention of severe respiratory viral infections causing acute respiratory failure in immunocompetent adults.
Methods: A narrative review of published clinical and experimental evidence was conducted. The review focused on respiratory viruses causing community-acquired severe respiratory infections in immunocompetent adults, excluding SARS-CoV-2 and herpesviruses. Evidence concerning molecular diagnostic techniques, respiratory support, antiviral therapy, immunomodulation, outcomes, and vaccination was synthesized.
Results: Multiplex PCR has improved detection of respiratory viruses and bacterial-viral co-infections, with reported viral detection rates varying according to the population and sampling method. Influenza, respiratory syncytial virus, and human metapneumovirus are important causes of severe disease. Viral epithelial injury, cell death, immune dysregulation, and diffuse alveolar damage contribute to respiratory failure. Bacterial co-infections and cardiovascular complications further increase mortality. Management remains primarily supportive, although oseltamivir remains central for severe influenza. Evidence for corticosteroids in viral pneumonia is limited and inconsistent. Vaccination provides an important strategy for reducing severe disease, particularly among older adults.
Conclusion: Respiratory viruses represent important causes of severe acute respiratory failure. Early molecular diagnosis, appropriate respiratory support, pathogen-directed treatment, prevention of co-infections, and vaccination are central to improving outcomes.
Maktab Mutlaq Al-Injaz for Academic Services
Title: Severe Acute Respiratory Failure Associated with Viral Respiratory Infections: A Multidisciplinary Approach to Diagnosis, Pharmacotherapy, Respiratory Support, and Critical Care Management
Description:
Background: Severe acute respiratory failure caused by respiratory viruses is an important cause of intensive care unit admission and is associated with substantial morbidity and mortality.
Advances in molecular diagnostics have increased the detection of respiratory viruses in lower respiratory tract infections, while also highlighting challenges in distinguishing true viral disease from asymptomatic carriage and bacterial-viral co-infection.
Respiratory viruses can cause direct epithelial injury, dysregulated inflammation, alveolar damage, and systemic complications.
Aim: This narrative review aimed to summarize current evidence on the epidemiology, molecular diagnosis, pathophysiology, clinical consequences, outcomes, treatment, and prevention of severe respiratory viral infections causing acute respiratory failure in immunocompetent adults.
Methods: A narrative review of published clinical and experimental evidence was conducted.
The review focused on respiratory viruses causing community-acquired severe respiratory infections in immunocompetent adults, excluding SARS-CoV-2 and herpesviruses.
Evidence concerning molecular diagnostic techniques, respiratory support, antiviral therapy, immunomodulation, outcomes, and vaccination was synthesized.
Results: Multiplex PCR has improved detection of respiratory viruses and bacterial-viral co-infections, with reported viral detection rates varying according to the population and sampling method.
Influenza, respiratory syncytial virus, and human metapneumovirus are important causes of severe disease.
Viral epithelial injury, cell death, immune dysregulation, and diffuse alveolar damage contribute to respiratory failure.
Bacterial co-infections and cardiovascular complications further increase mortality.
Management remains primarily supportive, although oseltamivir remains central for severe influenza.
Evidence for corticosteroids in viral pneumonia is limited and inconsistent.
Vaccination provides an important strategy for reducing severe disease, particularly among older adults.
Conclusion: Respiratory viruses represent important causes of severe acute respiratory failure.
Early molecular diagnosis, appropriate respiratory support, pathogen-directed treatment, prevention of co-infections, and vaccination are central to improving outcomes.
Related Results
LB2306. Population Pharmacokinetic (PPK), Pharmacokinetic/Pharmacodynamic attainment (PTA), and Clinical Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Sulbactam-Durlobactam (SUL-DUR) to Support Dose Selection for the Treatment of Acinetobacter baum
LB2306. Population Pharmacokinetic (PPK), Pharmacokinetic/Pharmacodynamic attainment (PTA), and Clinical Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Sulbactam-Durlobactam (SUL-DUR) to Support Dose Selection for the Treatment of Acinetobacter baum
Abstract
Background
SUL-DUR is a β-lactam/β-lactamase inhibitor combination in development for the treatment of ABC infections, ...
619. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Epetraborole Dose Selection for the Treatment of Patients with Mycobacterium avium Complex (MAC) Lung Disease
619. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Epetraborole Dose Selection for the Treatment of Patients with Mycobacterium avium Complex (MAC) Lung Disease
Abstract
Background
Epetraborole (EBO) is an orally available, bacterial leucyl transfer RNA synthetase inhibitor that concentra...
593. Population Pharmacokinetic Model Development for Epetraborole and Mycobacterium avium Complex (MAC) Lung Disease Patients Using Data from Phase 1 and 2 Studies
593. Population Pharmacokinetic Model Development for Epetraborole and Mycobacterium avium Complex (MAC) Lung Disease Patients Using Data from Phase 1 and 2 Studies
Abstract
Background
Epetraborole (EBO), an orally available bacterial leucyl transfer RNA synthetase inhibitor with potent activ...
Frequency of Common Chromosomal Abnormalities in Patients with Idiopathic Acquired Aplastic Anemia
Frequency of Common Chromosomal Abnormalities in Patients with Idiopathic Acquired Aplastic Anemia
Objective: To determine the frequency of common chromosomal aberrations in local population idiopathic determine the frequency of common chromosomal aberrations in local population...
592. Impact of Elevated MIC Values on Echinocandin Pharmacokinetic-Pharmacodynamic (PK-PD) Candida glabrata Target Attainment (TA)
592. Impact of Elevated MIC Values on Echinocandin Pharmacokinetic-Pharmacodynamic (PK-PD) Candida glabrata Target Attainment (TA)
Abstract
Background
Given the increasing prevalence of non-albicans Candida species, including C. glabrata and C. auris, which h...
Evolution of Antimicrobial Resistance in Community vs. Hospital-Acquired Infections
Evolution of Antimicrobial Resistance in Community vs. Hospital-Acquired Infections
Abstract
Introduction
Hospitals are high-risk environments for infections. Despite the global recognition of these pathogens, few studies compare microorganisms from community-acqu...
Organisatie van geestelijke gezondheidszorg voor mensen met een ernstige en persisterende mentale aandoening
Organisatie van geestelijke gezondheidszorg voor mensen met een ernstige en persisterende mentale aandoening
1 INTRODUCTION AND RESEARCH QUESTIONS 5 -- 2 GENERAL BACKGROUND: DEFINITIONS AND SCOPE OF THE STUDY 7 -- 2.1 CHRONIC AND COMPLEX MENTAL DISORDERS: DEFINITIONS AND SCOPE OF THE -- S...
The journey of pediatric ECMO
The journey of pediatric ECMO
Introduction:
Extracorporeal membrane oxygenation (ECMO) is an adaptation of conventional cardiopulmonary bypass techniques used for long-term support of respir...

